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Received July 12, 2014; accepted April 6, 2015AbstractBackground: It has been previously reported that melittin, the main ingredient of honey bee venom, has anticancer properties. However, there
appears to be no earlier study focusing on the isolation of melittin from Iranian honey bee venom (Apis mellifera meda), and evaluation of its
effect on cancerous cells.
Methods: We isolated melittin using reversed-phase high performance liquid chromatography, and its potential toxicity on gastric cancer AGS
cells was determined with an MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay. Furthermore, to ascertain whether
melittin induces apoptosis or necrosis in these cells, morphological evaluation, DNA fragmentation assay, propidium podide and annexin-V-
FITC dual staining, and flow cytometric analysis were also conducted.
Results: The results of our study suggested that melittin inhibited the proliferation of AGS cells in a dose and time-dependent trend. All of the
above four distinct assays indicated that melittin induces necrosis in AGS cells at concentrations of  1 mg/mL.
Conclusion: The present study indicated that melittin has an anticancer effect on gastric cancer AGS cells and stimulates necrotic cell death in
these cells.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Gastric cancer (GC) is one of the most common cancers in
the world, in that ~1 million new cases of GC and > 700,000
deaths (12% of all cancer related deaths) are reported each
year.1 Unfortunately, current strategies in GC therapy are most
of the time essentially ineffective.2 Regarding this matter, there
is an urgent need for the global medical community toConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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lethal disease. Various natural substances have been recognized
as having anticancer properties.3,4 One of these natural prod-
ucts is bee venom (BV) and its principal ingredient, melittin.5
Melittin (C131H229N39O31) is a cationic 26 amino acid
residue long peptide and is reported to have strong hemolytic
activity.6 The first 20 residues (N-terminal) of the structure of
melittin are predominantly hydrophobic amino acids, whereas
the carboxyl-terminal of the peptide is mostly composed of
hydrophilic residues.7 This amphipathic entity allows the
peptide to interact with phospholipid membranes.8
The effect of melittin on various cancer cell lines has been
investigated broadly and its inhibitory effect on the proliferation
of these cells has been demonstrated. In addition, it has beenociation. All rights reserved.
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death in cancerous cells. Induction of apoptosis by melittin or
BV has been reported in human lung cancer,9 rheumatoid
arthritis,10 hepatocellular carcinoma,11 human leukemic cells,12
human breast cancer,13 prostate,14 and ovarian cancer cells.15 It
seems that melittin-induced apoptosis is mediated through the
activation of the caspase-dependent pathway.4 However, other
studies have shown that melittin exhibits necrotic cytotoxicity
in rat thymocytes,16 murine skeletal muscles,17 erythrocytes18,
lymphocytes,19 lymphoblastoid cells,20 and Caco-2 cells.21
Identification of the precise mechanism of the effect of melit-
tin on cancerous cells plays an important role in the future
therapeutic application of this interesting peptide.
Apis mellifera meda (A. m. meda) is smaller than the Eu-
ropean honey bee, and produces less honey and is more
aggressive.22 European honey BV has been studied exten-
sively.23,24 However, there are no published reports regarding
the antiproliferative activity of A. m. meda venom compo-
nents, especially melittin, on human gastric adenocarcinoma
cell line (AGS) cells. The present study aimed to isolate
melittin from Iranian honey BV and to evaluate its inhibitory
effect on the proliferation of the gastric cancer AGS cell line.
2. Methods2.1. ChemicalsWe purchased 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-
2H-tetrazolium bromide (MTT), dimethyl sulfoxide, tri-
flouroacetic acid (TFA), acetonitrile, and melittin from Sig-
maeAldrich (St. Louis, MO, USA). Annexin V-FITC
Apoptosis Detection Kit (K-101-100) was obtained from Bio
Vision (Mountain View, CA, USA). The materials that were
used in the cell culture included RPMI-1640, fetal bovine
serum (FBS), and antibiotics, and were purchased from Sig-
maeAldrich (St. Louis, MO, USA).2.2. BeesA hive of Iranian honey bees were selected and checked for
disease and race. This hive was located in a bee keeping farm
in the Koohrang region, Chaharmahal and Bakhtiari, a South-
West province of Iran.2.3. Bee venom collectionHoney BV was collected according to the electrical stim-
ulation method25 with a slight modification. Briefly, the wired
glass plate of the venom collector was placed inside (top) of
the hive. When bees covered the surface of the wired glass
plate, the wires were electrified and a mild shock was applied
to the bees for 10 seconds and then the current stopped for 20
seconds. In this method, the bees sting the surface of the glass
plate in response to the electrical stimulation. Secreted venom
from the bees' sting dried rapidly exposed to the air. Dried
venom was scraped off with a sharp scalpel and transferred to
the laboratory.2.4. Venom profiling and isolation of melittinCollected venom was dissolved in 1 mL ultra-pure water
and then centrifuged at 16,000g for 10 minutes at room tem-
perature. Soluble supernatant was filtered through a 0.2 mm
membrane filter and stored at 20C. In order to facilitate
venom profiling and melittin isolation a high performance
liquid chromatography (HPLC) system (Dr. Ing. Herbert
Knauer GmbH, Berlin, Germany) was used. The HPLC system
consisted of the following instruments: pump K-1000, UV
detector 2550, manual injector with 20 mL loop, a computer
system with ChromGate software, and a C18 column (Knauer,
Eurosfer-100 C18, 250 mm  4.6 mm). TFA/Water (1:1000)
and TFA/ACN (1:1000) were used as solvent A and B,
respectively. Flow rate was established as 1 mL/min in all of
the separation processes. A linear gradient of 0e60% solvent
B was applied for 55 minutes and the column elute monitored
at 214 nm wavelength. The retention time of the isolated
melittin was compared with an external standard (Sigma-
Aldrich). The purity of the isolated melittin was evaluated
with the same HPLC method. The melittin fraction was
manually collected and lyophilized in a freeze dryer (Christ 2
alpha, Osterode am Harz, Germany).2.5. Hemolytic activityA hemolytic activity assay was performed according to the
previously described method with slight modification.26
Briefly, 2% red blood cells (RBC) suspension were trans-
ferred to a 96-well plate (100 mL per well). The RBCs were
treated with melittin at final concentrations of 8 mg/well, 4 mg/
well, 2 mg/well, 1 mg/well, 0.5 mg/well, 0.25 mg/well,
0.125 mg/well, and 0.0625 mg/well. The amount of 100 mL of
supernatant from each well were transferred gently to a new
96-well plate and the optical density of released hemoglobin
was measured at 540 nm with a microplate spectrophotometer
(Epoch, BioTek, Luzern, Switzerland). The data were
compared of a positive control (100 mL RBC and 100 mL
Triton X-100 1%) and a negative control (100 mL RBC and
100 mL phosphate buffered saline), and all experiments were
performed in triplicate. The percent of hemolysis was calcu-
lated as follows:
Hemolysis percent ¼ ½ODðoptical densityÞ540ðSampleÞ
OD540ðNeg:controlÞ=ðOD540ðPos:controlÞ
OD540ðNeg:controlÞÞ  1002.6. Cell cultureAGS cell line was purchased from the Pasteur Institute of
Iran Cell Bank (Tehran, Iran). AGS cells were cultured in
RPMI-1640 medium supplemented with 10% FBS, penicillin
100 unit/mL, and streptomycin 100 mg/mL. Cultures were
maintained at 37C in a humidified atmosphere of 5% CO2
and 95% air.
Fig. 1. Iranian honeybee venom chromatogram. A linear gradient method with 0e60% gradient of Solvent B for 55 minutes was applied and column eluates were
monitored at 214 nm wavelength. Reverse phase-high performance liquid chromatography was performed using a C18 column (Knauer, Eurosfer-100 C18,
250  4.6 mm). Flow rate was 1 mL/min in the entire process.
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Fig. 2. Reverse phase-high performance liquid chromatography of mixed melittin from Iranian honey bee venom and a standard (Sigma) which shows similar
retention times. This experiment was done to demonstrate that the purified melittin in this study contains the same retention time as a standard one.
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density of 4.5  104 cells/well in 200 mL FBS supplemented
medium. Then, the cells were treated with melittin (diluted in
FBS free medium) at final concentrations of 8 mg/mL, 4 mg/
mL, 2 mg/mL, 1 mg/mL, 0.5 mg/mL, and 0.25 mg/mL and
incubated for 6 hours, 12 hours, and 24 hours. Four hours
before ending the incubation time, 20 mL MTT salt (2.5 mg/
mL) were added to each well and plates were returned to the
incubator for completion of incubation time. At the end, plates
were centrifuged (1500g, 10 minutes) and the supernatantswere then removed. Thereafter, 100 mL dimethyl sulfoxide
was added to each well in order to dissolve the formazan salt.
Plates were shaken and the optical density of each well was
measured at 570 nm with a microplate spectrophotometer
(Epoch, BioTek, Luzern, Switzerland). Untreated cells were
considered as the control group. The percentage of viability
percent was calculated as follows:
Viability percent ¼ ½ðOD570ðMelittin treated sampleÞ=OD570ðcontrolÞÞ
 100:
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Fig. 3. Chromatogram for controlling the purity of isolated melittin. Isolated melittin freeze-dried and subjected to reverse phase-high performance liquid
chromatography with the same method as Fig. 2. Retention time is shown at 42 minutes, the same as the external standard.
577A. Mahmoodzadeh et al. / Journal of the Chinese Medical Association 78 (2015) 574e5832.8. Morphological evaluationIn order to characterize melittin-induced cell death in AGS
cells, treated cells with 2 mg/mL, 1 mg/mL, and 0.5 mg/mL
melittin for 12 hours were observed using an inverted micro-
scope with phase contrast objectives (INV100-FLBEL Engi-
neering srl, Monza, Italy). Morphology of the treated cells was
then compared with untreated cells.Fig. 4. Hemolytic activity assay. The percentage of hemolytic activity of
melittin was determined in comparison with positive control (Triton X-100).
Results are presented as mean ± standard deviation. Experiments were done in
triplicate and the significance was determined using the Student t test
( p < 0.05 vs. untreated control).Moreover, in a separate experiment, the cells were stained
with propidium iodide (PI) and AnnexinV-FITC (AnV-FITC)
and observed using an inverted fluorescence microscope
(INV100-FL, BEL Engineering). The cells were plated in a
24-well plate at a density of 1  105 and treated with 2 mg/mL,
1 mg/mL, and 0.5 mg/mL concentrations of melittin for 12
hours. AGS cells were harvested and stained with equal vol-
umes of PI and AnV-FITC and incubated for 5 minutes at
room temperature in the dark. Then the cells were placed on aFig. 5. Cytotoxicity of melittin on AGS cell line was determined via MTT
assay. Results are presented as mean ± standard deviation. Experiments were
done in triplicate and significance was determined using the Student t test
( p < 0.05 vs. untreated control).
Fig. 6. Effect of isolated melittin from Iranian honey bee venom on morphology of AGS cell line. (A) Control; (B) cells were treated with 0.5 mg/mL melittin; (C)
1 mg/mL 1 melittin; and (D) 2 mg/mL melittin and observed using a phase-contrast microscope. Cell shrinkage, irregularity in cellular shape, cellular detachment
and serious damage to cell membrane were observed in the melittin-treated cultures, but not in the control.
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were observed under an inverted fluorescence microscope
using a green filter set for FITC and a blue filter set for PI.2.9. DNA fragmentation assayIn order to detect apoptotic DNA cleavage, DNA frag-
mentation assay was performed. At first, 1  106 AGS cells
were plated in each well of a 6-well plate and treated with
2 mg/mL, 1 mg/mL, and 0.5 mg/mL melittin for 12 hours. Then,
the cells were harvested and lysed with lysis buffer (Tris
10mM, ethylenediaminetetraacetic acid 1mM, and sodium
dodecyl sulfate 1%) and the lysates were incubated with 10 mL
RNase A at 37C for 30 minutes followed by treatment with
10 mL proteinase K (2 mg/mL) at 56C for 1 hour.
DNAwas precipitated by adding 5 mL potassium acetate and
30 mL ice cold absolute ethanol and then centrifuged (1500g, 10
minutes). Precipitated DNA was then washed in 70% ethanol
and diluted in 50 mL Tris-EDTA buffer. Finally, the extracted
DNA was analyzed with agarose gel electrophoresis (1.2%,
containing ethidium bromide) at 5 V/cm for 1 hour. At the end,
gel was visualized and photographed in a gel documentation
system (Bio-Rad Laboratories, Hercules, CA, USA).2.10. Flow cytometric analysisAs morphological evaluation is a qualitative method, to
analyze quantitatively the rates of necrosis and apoptosis
induced by melittin, we performed flow cytometric analysis.
Flow cytometric analysis was performed using an AnV-FITC
Apoptosis Detection Kit (K-101-100, Bio Vision), according
to the manufacturer's instruction. Briefly, cells were plated in
6-well plates at a density of 1  106 cells/well and treated with
0.5 mg/mL, 1 mg/mL, and 2 mg/mL melittin concentrations for
12 hours. Then, the cells were harvested and resuspended in
500 mL binding buffer in 1.5 mL micro tube. A total of 5 mL PIand 5 mL AnV-FITC were added to each well and placed at
room temperature (RT) for 5 minutes in the dark. Finally, the
samples were analyzed using a flow cytometer (CyFlowSL,
Partec GmbH, Munster, Germany) at 488 nm. Histograms
were plotted using Flomax software (Partec GmbH). The
populations of viable (AnV-FITC, PI), apoptotic (AnV-
FITCþ, PI), and necrotic (AnV-FITC; PIþ, and AnV-
FITCþ; PIþ) cells are represented in the lower left, lower right
and upper right, and upper left quadrants, respectively.
3. Results3.1. Reverse phase-HPLCIn the current study, a reverse phase (RP)-HPLC system
with a C18 column was used to facilitate venom profiling and
isolation of melittin from Iranian honey BV. The column
elutes were monitored at 214 nm wavelength, and a chro-
matogram of A. m. meda venom is presented in Fig. 1. In this
chromatogram, > 100 different peaks are detectable; how-
ever, < 20 major peaks are obvious. Melittin eluted 42 mi-
nutes after injection of venom at 40% acetonitrile, which was
close to the retention time of the external standard (melittin,
sigma; Figs. 2 and 3). To control the purity of the isolated
melittin, it was subjected to RP-HPLC using the same method
(Fig. 3). The fraction of melittin was manually collected,
lyophilized, and stored at 20C to be used in subsequent
biological assays.3.2. Hemolytic activityHemolytic activity assay indicated that the purified melittin
from A. m. meda venom showed a strong hemolytic activity.
According to the results (Fig. 4), isolated melittin exhibited
complete hemolytic activity at concentrations above 1 mg/mL.
Melittin did not show considerable toxic effect at very low
Fig. 7. Characterization of melittin induced cell death in AGS cells. (A) Normal cells; (B,F) cells were treated with 0.5 mg/mL melittin; (C,G) 1 mg/mL melittin;
(E,H) 2mg/mL melittin and stained with annexin-V-FITC and propidium iodide-A. A fluorescent-invert microscope was used to observe the stained cells. No
significant increase was observed in annexin-V-FITC stained cells (BeD) by increasing melittin concentration in comparison with control cells (A). Propidium
iodide-A intensity was increased in higher melittin concentrations (FeH).
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value, which is the concentration of melittin which shows 50%
hemolytic activity of the positive control, was determined to
be 0.5mg/mL.3.3. Cytotoxicity assayIn order to determine the potential toxic effect of melittin
on an AGS cell line, MTT assay was performed. Cells were
plated in 96-plates and treated with melittin at final concen-
trations of 0.125 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL,
2 mg/mL, 4 mg/mL, and 8 mg/mL for 6 hours, 12 hours, and 24
hours. The viability of AGS cells treated with melittin at the
above-mentioned concentrations for 6 hours was 93.74 ± 3.29,
81.42 ± 5.98, 76.42 ± 6.64, l62.13 ± 7.49, 18.80 ± 4.85,
13.17 ± 1.72, and 11.05 ± 1.90, respectively. The viability ofAGS cells treated with melittin at the above concentrations for
12 hours were 90.60 ± 7.39, 76.23 ± 3.00, 71.10 ± 5.00,
60.24 ± 4.60, 26.30 ± 5.00, 9.39 ± 1.37, and 10.02 ± 2.10,
respectively. The viability of AGS cells treated with melittin at
the above concentrations for 24 hours was 89.47 ± 5.56,
67.61 ± 6.09, 61.70 ± 5.44, 54.82 ± 7.70, 10 ± 1.29,
9.55 ± 0.44, and 9.32 ± 0.29, respectively.
These results showed that isolated melittin from A. m. meda
venom has a cytotoxic effect on AGS cell lines (Fig. 5). Based
on the results of the MTT assay, doses, and treatment times of
melittin for use in subsequent experiments was set at 0.5 mg/
mL, 1 mg/mL, and 2 mg/mL for 12 hours.3.4. Morphological evaluationsTo indicate the effect of melittin on AGS cells morphology,
cells were treated with various concentrations of melittin
Fig. 8. DNA fragmentation assay. AGS cells were incubated for 12 hours
without melittin and with 0.5 mg/mL, 1 mg/mL, and 2 mg/mL of melittin.
Genomic DNA was extracted and analyzed with electrophoresis on a 1.2%
agarose gel containing ethidium bromide. Melittin treated AGS cells did not
show apoptotic DNA fragmentation pattern. A ¼ 0.5 mg/mL; B ¼ 1 mg/mL;
C ¼ control; D ¼ 2 mg/mL of melittin; M ¼ marker.
580 A. Mahmoodzadeh et al. / Journal of the Chinese Medical Association 78 (2015) 574e583(0.5 mg/mL, 1 mg/mL, and 2 mg/mL) for 12 hours. After the
desired treatment time (12 hours), for morphology, the images
were taken with a microscope under 20  magnification. As
shown in Fig. 6, necrotic cell death hallmarks including loss of
membrane integrity is obvious in the cells which are treated
with 1 mg/mL and 2 mg/mL melittin. However, these signs
were absent in the control group or less in the low treated
(0.5 mg/mL) cells. These results suggest that melittin causes
serious damage to AGS cell membranes leading to necrosis.
Furthermore, in order to gather more precise information
about the kind of melittin that induced death in AGS cells, PI/
AnV-FITC staining was performed. Cells were treated with
melittin (0.5 mg/mL, 1 mg/mL, and 2 mg/mL for 12 hours), and
stained with PI and AnV-FITC dyes. Stained cells were
observed with a fluorescent invert microscope.
As presented in Figs. 7Be7D, there is no significant in-
crease in the intensity of AnV-FITC fluorescent in the cells
treated with melittin. This means that translocation of the
phosphatidylserine (an apoptotic hallmark) did not happen by
treating the cells with melittin, significantly. By contrast, PI
stained cells increased by an increase in the concentration of
melittin (0.5 mg/mL, 1 mg/mL, and 2 mg/mL; Figs. 7Fe7H).
Normal cells are shown in Fig. 7A.3.5. DNA fragmentationTo assert the induction of necrotic death with melittin in an
AGS cell line, DNA fragmentation assay was performed. The
genomic DNA was isolated from treated cells with melittin
and untreated cells (as negative control) and analyzed withagarose gel electrophoresis. As shown in Fig. 8, treatment of
AGS cells with melittin (0.5 mg/mL, 1 mg/mL, and 2 mg/mL
for 12 hours) did not result in fragmentation of DNA. From the
DNA fragmentation assay it seems that melittin exhibits
necrotic cytotoxicity on AGS cells. However, additional
studies need to be undertaken to provide additional evidence
of the melittin's necrotic cytotoxicity in wider and more
diverse patient populations.3.6. Flow cytometric analysisTo gain a quantitative analysis of melittin-induced cell
death in an AGS cell line, PI/An V-FITC dual staining was
performed and analyzed using a flow cytometer. For this
purpose untreated cells were used as negative control. As
shown in Fig. 9A, 98% of the control population is viable (PI/
An V-FITC negative) and an insignificant percent is apoptotic
or dead (a total of 1.44%).
After treatment of AGS cells with 0.5 mg/mL melittin for
12 hours, the population divided into four different portions:
79.26% viable, 5.66% apoptotic, 2.58% late apoptotic or
necrotic, and 12.51% necrotic cells (Fig. 9B). In treated cells
with 1 mg/mL in comparison with previous concentrations, a
significant increase in the percent of necrotic cells (30.45%)
and in necrotic or late apoptotic cells (18.83%) were observed
and viable cells decreased to 45% (Fig. 9C). However, no
significant change was observed in the percent of apoptotic
cells (5%). Finally, the percent of necrotic cells in 2 mg/mL
melittin treated AGS cells increased to 58%. The percent of
apoptotic cells in this concentration was just 0.62% (Fig. 9D).
These data showed that melittin exhibits necrotic toxicity at
0.5 mg/mL, 1 mg/mL, and 2 mg/mL concentrations on AGS
cells.
4. Discussion
GC is the fourth most common cancer in the world and is a
disease with a prohibitively high death rate.27,28 After lung
cancer, it's the second leading cause of cancer-related deaths.29
Surgery, chemotherapy, or radiation can be used in the treat-
ment of GC. Sometimes during surgical intervention, the main
treatment strategy is to remove the entire stomach in order to
prevent the tumor from spreading. In fact, surgeons may
remove a part of the intestine or pancreas in late diagnosed
cases. Unfortunately, stomach cancer may respond very poorly
to chemotherapy. Subsequent to surgery, if chemotherapy is
used, it is often just to reduce the tumor size and symptoms.
As there is no reliable therapeutic strategy, it is necessary to
find new and more efficient approaches in GC therapy. During
the past several years, melittin has been considered as an ideal
candidate to be used in cancer therapy.12 Melittin is a powerful
cationic antimicrobial peptide.30 It comprises 40e50% of the
dried venom and causes disruption of normal cellular activity
and cell lysis.31
BV has been used as a pain killer and antirheumatoid agent
in oriental medicine.4,10 Also it has been reported that BV and
its main ingredient (melittin) shows anticancer properties.4
Fig. 9. Melittin shows necrotic toxicity on AGS cell line. (A) Untreated cells; (B) cells were treated with 0.5 mg/mL melittin; (C) 1 mg/mL melittin; and (D) 2 mg/
mL of melittin for 12 hours and compared with untreated AGS cells, as a negative control. Cells were stained with propidium iodide-A and annexin-V-FITC and
analyzed with a flow cytometer (CyFlowSL, Partec GmbH, Munster, Germany).
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cancerous cells has been investigated extensively.4 However,
the mechanism of BV or melittin-induced cell death in these
cells is not completely understood. It is speculated that the
cytotoxic effect of melittin is mediated through the formation
of channels on cell membranes. Furthermore, there is another
hypothesis that proposes a detergent-like model interaction of
melittin and membranes. The present study is the first report
about the isolation of melittin from Iranian honey BV and the
evaluation of its effect on gastric cancer AGS cells. It is
believed that melittin can be used to arrest proliferation of GC
cells, and have a profound effect by facilitating melittin-
induced death in gastric cancer AGS cells.
In order to isolate melittin from the BV, RP-HPLC was
performed and the resulting chromatogram showed that
melittin constituted almost 50% of Iranian honey BV: this
result was consistent with the reports about European honey
BV components.32 Purified melittin showed the same retention
time with standard melittin in HPLC. The biological activityof purified melittin was subjected to a hemolytic activity assay.
The results of the hemolytic activity assay exhibited high
hemolytic activity of isolated melittin (HD50 ¼ 0.5 mg/mL).
The toxicity of melittin on an AGS cell line was assessed with
MTT assay at various concentrations of melittin (8 mg/mL,
4 mg/mL, 2 mg/mL, 1 mg/mL, 0.5 mg/mL, 0.25 mg/mL, and
0.125 mg/mL) for 6 hours, 12 hours, and 24 hours. The MTT
assay showed that melittin is able to arrest the proliferation of
AGS cells at a very low concentration (0.5 mg/mL). Also, this
experiment showed that melittin has a dose and time depen-
dent toxicity on AGS cells.
Numerous studies concerning the cytotoxic effects of BV
and melittin were performed from 1980 to 2000. However, the
mechanisms of this cytotoxicity were investigated in the past 10
years.4 The latest studies have focused on the mechanism of BV
and melittin-induced cell death. It has been reported that BVor
melittin induce apoptosis or necrosis in some of the cells. It
would appear that melittin-induced death is dependent on cell
type and the amount of the toxin. Many chemotherapeutic
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agents act in a similar manner; for example, many of them
activate p53. In cancer therapy, apoptosis is preferable to ne-
crosis, because apoptosis does not produce inflammation and
damage to surrounding normal tissue.34 Melittin has anticancer
effects on GC AGS cells and stimulates necrotic cell death.
However we think that necrosis can be useful to induce a more
powerful immune system response against the cancer.
A morphological evaluation of treated AGS cells showed a
looseness of cell membrane integrity in the presence of 1 mg/
mL and 2 mg/mL melittin, which was a sign of necrotic cell
death. Furthermore, DNA fragmentation assay indicated that
melittin does not stimulate caspases-activated DNA digestion,
one of the apoptotic hallmarks. This regular enzymatic
cleavage produces 180e200 bp nucleosomal fragments,35
which were not observed in this study. Finally, the effect of
melittin on translocation of the phosphatidylserine and cell
membrane integrity was evaluated using PI/An V-FITC dual
staining with flow cytometry and fluorescence microscopy.
The results of PI/An V-FITC dual staining demonstrated that
melittin acts as a necrotic agent in AGS cell lines.
The best anticancer drug is a highly toxic agent against
cancer cells that does not cause excessive damage to normal
cells. Nowadays, an important aspect of medical research is
focused on the synthesis, finding, and/or modification of
different substances in order to introduce a useful anticancer
drug. Natural products have a special importance in these
studies. Melittin is one of these natural products, which could
be an ideal candidate against cancer. The big obstacle in the
clinical usage of melittin as an anticancer drug, is the extent of
its toxicity on normal cells. In spite of this undesirable prop-
erty of melittin, it can be used as a considerable anti-
inflammatory, antibacterial, antifungal, and antitumor pep-
tide. In order to decrease the toxic effect of melittin on normal
cells, different strategies including gene therapy, encapsulation
of melittin, and conjugation with antibodies have been sug-
gested.36 These strategies may be used in the near future to
selectively control tumor cells by the introduction of melittin.
In the current study, in three distinct assays, morphological
evaluation, DNA fragmentation, and flow cytometric analysis,
no evidence of apoptosis was observed. The used concentra-
tions of melittin in these tests were selected based on the re-
sults of the MTT assay. These concentrations ranged from a
low toxic concentration (0.5 mg/mL) to a high toxic concen-
tration (2 mg/mL).
In conclusion, our study has demonstrated that melittin
inhibits the proliferation of GC AGS cells in a dose and time
dependent trend. Additionally, it would appear that melittin
stimulated necrosis in lethal cancer cells. We believe that these
findings are noteworthy and represent an important achieve-
ment in the use of melittin to create better and more effective
treatments for GC.
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